3 results
Approved WMOCompleted
The aim of this study is to quantify residual ER binding sites during fulvestrant therapy, compared to the tracer uptake prior to fulvestrant therapy.
Approved WMOCompleted
Objectives: The primary objectives of this study are: • Part 1 (dose-escalation): To evaluate the safety of SYD985 in combination with niraparib to determine the maximum tolerated dose (MTD) and recommended combination dose regimen for expansion (…
Approved WMOCompleted
The purpose of the study is to determine the safety and assess the efficacy of the combination of radium-223 dichloride and pembrolizumab in participants with stage IV NSCLC with bone metastases who are either treatment naïve or have progressed on…